TradingView
AlenCiken
1 กรกฎา 2020 เวลา 20 นาฬิกา 31 นาที
Strongly Positive Histological Data
NASDAQ:AKRO
60
Akero Therapeutics, Inc.
NASDAQ
คำอธิบาย
⋅
1 กรกฎา 2020 เวลา 20 นาฬิกา 31 นาที
Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients
48% fibrosis improvement of at least one stage without worsening of NAS across all dose groups, with a 62% response rate for the 50mg dose group
28% fibrosis improvement of at least two stages across all dose groups, with a 38% response rate for the 50mg dose group
48% NASH resolution without worsening of fibrosis across all dose groups, with a 54% response rate for the 50mg dose group
ir.akerotx.com/news-releases/news-release-details/akero-announces-strongly-positive-histological-data-across-all
Fundamental Analysis
Trend Analysis
Chart Patterns
เพิ่มเติม